Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C | Zendy

Susanggie | Zendy; Kristen Marks | Zendy; Michael D. Hughes | Zendy; Daniel S. Fierer | Zendy; Christine E. MacBrayne | Zendy; Arthur Kim | Zendy; Kimberly Hollabaugh | Zendy; Jhoanna Roa | Zendy; B. Symonds | Zendy; Diana M. Brainard | Zendy; John G. McHutchison | Zendy; Marion G. Peters | Zendy; Jennifer J. Kiser | Zendy; Raymond T. Chung | Zendy

Open Access

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

Author(s) -

Susanggie,

Kristen Marks,

Michael D. Hughes,

Daniel S. Fierer,

Christine E. MacBrayne,

Arthur Kim,

Kimberly Hollabaugh,

Jhoanna Roa,

B. Symonds,

Diana M. Brainard,

John G. McHutchison,

Marion G. Peters,

Jennifer J. Kiser,

Raymond T. Chung

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix025

Subject(s) - medicine , ribavirin , sofosbuvir , cohort , hepatitis c virus , hepatitis c , interquartile range , pegylated interferon , immunology , virus

Historically, acute hepatitis C virus (HCV) infection was treated with shorter durations of interferon-containing therapies. In the era of direct-acting antivirals (DAAs), it is unclear whether the efficacy of treatment achieved in chronic infection can be maintained with abbreviated courses of therapy during the acute phase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research